Study:
An Intergroup Randomized Phase II Study of Bevacizumab (NSC 704865) or Cetuximab (NSC 714692) in Combination With Gemcitabine and in Combination With Chemoradiation (Capecitabine and Radiation) in Patients With Completely-Resected Pancreatic Carcinoma
Rationale:
Monoclonal antibodies, such as bevacizumab and cetuximab, can block tumor growth
in different ways. Some block the ability of tumor cells to grow and spread. Others find
tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may
also stop the growth of tumor cells by blocking blood flow to the tumor. Cetuximab may also
stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs
used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Radiation therapy uses high-energy x-rays to kill tumor cells. Giving bevacizumab or
cetuximab together with gemcitabine, capecitabine, and radiation therapy after surgery may
kill any tumor cells that remain after surgery. It is not yet known whether bevacizumab is
more effective than cetuximab when given together with gemcitabine, capecitabine, and
radiation therapy in treating pancreatic cancer.
Purpose:
This randomized phase II trial is studying bevacizumab to see how well it works
compared to cetuximab when given together with gemcitabine, capecitabine, and radiation
therapy in treating patients with pancreatic cancer that has been completely removed by
surgery.
Study Status: Active, not recruiting
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Pancreatic Cancer |
Biological: bevacizumab
Biological: cetuximab
Drug: capecitabine
Drug: gemcitabine hydrochloride
Radiation: radiation therapy |
Phase 2 |
Verified by
National Cancer Institute (NCI)
October, 2008
Sponsored by: National Cancer Institute (NCI)
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00305877
Study Type: Interventional
Study Design: Allocation: Randomized, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Community Oncology Group at Cleveland Clinic Cancer Center
Independence, Ohio 44131
United States
Cleveland Clinic - Wooster
Wooster, Ohio 44691
United States
Jordan D. Berlin, MD., Study Chair
Arthur William Blackstock, MD., Study Chair
Andrew M. Lowy, MD., Study Chair
Robert McWilliams, MD., Study Chair